Maria S. Andres

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

Journal: European heart journal

Published: July 06, 2026

Machine learning-enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality.

Machine learning-enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality.

Journal: European heart journal. Digital health

Published: February 18, 2026

Dyslipidaemias in cancer patients.

Dyslipidaemias in cancer patients.

Journal: European heart journal

Published: June 10, 2025

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.

Journal: BMJ open

Published: February 05, 2025

Immunotherapy and the heart: Understanding the cardiovascular risks of immune checkpoint inhibitors.

Immunotherapy and the heart: Understanding the cardiovascular risks of immune checkpoint inhibitors.

Journal: Presse medicale (Paris, France : 1983)

Published: October 21, 2024

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity.

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity.

Journal: Current oncology reports

Published: August 13, 2024

Complementary use of cardiac magnetic resonance and 18 F-FDG positron emission tomography imaging in suspected immune checkpoint inhibitor myocarditis.

Complementary use of cardiac magnetic resonance and 18 F-FDG positron emission tomography imaging in suspected immune checkpoint inhibitor myocarditis.

Journal: Cardio-oncology (London, England)

Published: June 22, 2024

The United Kingdom's First Cardio-Oncology Service: A Decade of Growth and Evolution.

The United Kingdom's First Cardio-Oncology Service: A Decade of Growth and Evolution.

Journal: JACC. CardioOncology

Published: May 22, 2024

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.

Journal: Cardio-oncology (London, England)

Published: May 13, 2024

Erratum for: Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity.

Erratum for: Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity.

Journal: Radiology. Cardiothoracic imaging

Published: February 15, 2024

Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity.

Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity.

Journal: Radiology. Cardiothoracic imaging

Published: January 11, 2024

Cancer therapy related cardiac dysfunction as a result of Panitumumab.

Cancer therapy related cardiac dysfunction as a result of Panitumumab.

Journal: Cardio-oncology (London, England)

Published: January 11, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026